1140 related articles for article (PubMed ID: 30844110)
21. [Advances in the Influence of EGFR Mutation on the PD-L1 Expression in Non-small Cell Lung Cancer].
Zhi X; Li W; Wang S; Wang J
Zhongguo Fei Ai Za Zhi; 2019 Dec; 22(12):779-785. PubMed ID: 31874674
[TBL] [Abstract][Full Text] [Related]
22. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
23. [A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].
Zhang H; Yang X; Li K; Wang J; Lv J; Li X; Zhang X; Qin N; Zhang Q; Wu Y; Ma L; Gai F; Hu Y; Zhang S
Zhongguo Fei Ai Za Zhi; 2021 Feb; 24(2):78-87. PubMed ID: 33478196
[TBL] [Abstract][Full Text] [Related]
24. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
[TBL] [Abstract][Full Text] [Related]
25. Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer.
Zhang H; Dutta P; Liu J; Sabri N; Song Y; Li WX; Li J
J Cell Mol Med; 2019 Jan; 23(1):535-542. PubMed ID: 30378264
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
[TBL] [Abstract][Full Text] [Related]
27. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
[TBL] [Abstract][Full Text] [Related]
28. Extracellular vesicles derived from lung cancer cells exposed to intermittent hypoxia upregulate programmed death ligand 1 expression in macrophages.
Liu Y; Lu M; Chen J; Li S; Deng Y; Yang S; Ou Q; Li J; Gao P; Luo Z; Yuan P; Tan J; Gao X
Sleep Breath; 2022 Jun; 26(2):893-906. PubMed ID: 34254261
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.
Minakata K; Takahashi F; Nara T; Hashimoto M; Tajima K; Murakami A; Nurwidya F; Yae S; Koizumi F; Moriyama H; Seyama K; Nishio K; Takahashi K
Cancer Sci; 2012 Nov; 103(11):1946-54. PubMed ID: 22863020
[TBL] [Abstract][Full Text] [Related]
30. Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer.
Zuo HX; Jin Y; Wang Z; Li MY; Zhang ZH; Wang JY; Xing Y; Ri MH; Jin CH; Xu GH; Piao LX; Ma J; Jin X
J Ethnopharmacol; 2020 Jul; 257():112835. PubMed ID: 32278762
[TBL] [Abstract][Full Text] [Related]
31. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.
Azuma K; Ota K; Kawahara A; Hattori S; Iwama E; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I
Ann Oncol; 2014 Oct; 25(10):1935-1940. PubMed ID: 25009014
[TBL] [Abstract][Full Text] [Related]
32. Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.
Shibahara D; Tanaka K; Iwama E; Kubo N; Ota K; Azuma K; Harada T; Fujita J; Nakanishi Y; Okamoto I
J Thorac Oncol; 2018 Jul; 13(7):926-937. PubMed ID: 29596910
[TBL] [Abstract][Full Text] [Related]
33. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.
Ota K; Azuma K; Kawahara A; Hattori S; Iwama E; Tanizaki J; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I
Clin Cancer Res; 2015 Sep; 21(17):4014-21. PubMed ID: 26019170
[TBL] [Abstract][Full Text] [Related]
34. [Advances of the Role of Lung Cancer Driver Gene and PD-1/PD-L1 Pathway Interaction in the Tumorigenesis and Progression of Non-small Cell Lung Cancer].
Shi Y; Lv W; Wang L; Hu J
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):781-786. PubMed ID: 29167009
[TBL] [Abstract][Full Text] [Related]
35. Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC.
Jiang L; Guo F; Liu X; Li X; Qin Q; Shu P; Li Y; Wang Y
Sci Rep; 2019 Mar; 9(1):3705. PubMed ID: 30842489
[TBL] [Abstract][Full Text] [Related]
36. MUC3A induces PD-L1 and reduces tyrosine kinase inhibitors effects in EGFR-mutant non-small cell lung cancer.
Luo Y; Ma S; Sun Y; Peng S; Zeng Z; Han L; Li S; Sun W; Xu J; Tian X; Wang F; Wu Q; Xiao Y; Zhang J; Gong Y; Xie C
Int J Biol Sci; 2021; 17(7):1671-1681. PubMed ID: 33994852
[TBL] [Abstract][Full Text] [Related]
37. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Han K; Zhang Y
J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 expressed from tumor cells promotes tumor growth and invasion in lung cancer via modulating TGF-β1/SMAD4 expression.
Chen MJ; Wang YC; Wang L; Shen CJ; Chen CY; Lee H
Thorac Cancer; 2022 May; 13(9):1322-1332. PubMed ID: 35373505
[TBL] [Abstract][Full Text] [Related]
39. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.
Lin A; Wei T; Meng H; Luo P; Zhang J
Mol Cancer; 2019 Sep; 18(1):139. PubMed ID: 31526368
[TBL] [Abstract][Full Text] [Related]
40. Expression of programmed death-ligand 1 and hypoxia-inducible factor-1α proteins in endometrial carcinoma.
Tawadros AIF; Khalafalla MMM
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1063-S1069. PubMed ID: 30539847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
